A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
Brief description of study
If you have been diagnosed with renal cell carcinoma (RCC; a type of kidney cancer) and are at a high risk of your disease coming back (disease recurrence) following either nephrectomy (surgical procedure to remove all or part of a kidney) or metastasectomy (removal of cancerous growth that has spread away from your kidney), you may qualify for this study. The goal of this phase III study is to compare the effects, good or bad, of atezolizumab versus placebo (an inactive substance that looks like atezolizumab) on you and your RCC to find out which is better.
Clinical Study Identifier: s16-01175
ClinicalTrials.gov Identifier: NCTs16-01175
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
